ALLGF - MacroGenics teams up with Alligator Bio to develop novel immunotherapy

MacroGenics (MGNX) and Alligator Bioscience (ALLGF) have collaborated to expand latter's proprietary patient specific immunotherapy Neo-X-Prime with MGNX's DART and TRIDENT multi-specific platforms against two undisclosed targets. Under the collaboration, which covers activities from candidate drug generation up until IND-enabling studies, each company will be responsible for its own costs.The parties may continue further development of the resulting bispecific molecule under a separate co-development agreement.MGNX shares rallied around 37% for YTD.MacroGenics' well-diversified portfolio stands out as a long-term buy and hold, says SA contributor Edmund Ingham in his article, MacroGenics: Pipeline Looks Very Attractive And Somewhat Overlooked.Source: Company Presentation

For further details see:

MacroGenics teams up with Alligator Bio to develop novel immunotherapy